EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.11.3 | Acquired Immunodeficiency Syndrome |
1353102 |
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
2
4
3
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1400960 |
Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
4
1
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1457191 |
Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. |
causal interaction
unassigned |
1
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1534641 |
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network. |
ongoing research
therapeutic application
unassigned |
3
2
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1613672 |
B-cell activation and differentiation by HIV-1 antigens among volunteers vaccinated with VaxSyn HIV-1. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
4
2
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1706607 |
Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1845391 |
Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1984386 |
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. |
ongoing research
therapeutic application
unassigned |
4
2
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
1993354 |
Effect of a recombinant HIV gp160 vaccine on monokine production. |
ongoing research
therapeutic application
unassigned |
2
4
0 |
| 3.4.11.3 | Acquired Immunodeficiency Syndrome |
2092787 |
Characteristics of a population volunteering for human immunodeficiency virus immunization. NIAID AIDS Clinical Trials Network. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
3
2
1
0 |
